Coagulopathy associated with extended-spectrum cephalosporins in patients with serious infections.
AUTOR(ES)
Nichols, R L
RESUMO
Patients enrolled in two double-blind multicenter studies were evaluated for the development of hypoprothrombinemia during treatment with cephalosporins. Patients with pneumonia or peritonitis received ceftizoxime, cefotaxime, or moxalactam. The incidence of hypoprothrombinemia was greater in patients with peritonitis (12 of 49) than in those with pneumonia (5 of 96; P less than 0.05). Overall, moxalactam was associated with a higher incidence of hypoprothrombinemia (13 of 52) than either ceftizoxime (1 of 43; P less than 0.05) or cefotaxime (3 of 50; P less than 0.05), and moxalactam patients incurred the highest average increase in prothrombin time (3.7 s) as compared with either ceftizoxime (0.5 s; P less than 0.05) or cefotaxime (0.9 s; P less than 0.05) patients. The occurrence of hypoprothrombinemia in moxalactam patients with peritonitis was not related to dosage, duration of therapy, age, sex, race, or renal or hepatic function. The degree of ileus was, however, strongly related to the development of coagulopathy in moxalactam-treated patients only.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174706Documentos Relacionados
- Disk diffusion interpretive criteria for extended-spectrum cephalosporins with Haemophilus influenzae.
- Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins.
- Extended-spectrum beta-lactamases.
- Insufficient Evidence that Extended-Spectrum Cephalosporins Effectively Prevent Metastatic Infections Related to Klebsiella pneumoniae-Caused Liver Abscess
- Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.
